Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage For the relief and treatment of severe pain.
Marketing Status Prescription; Discontinued
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Cardiac arrhythmiasMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
Cardiac arrhythmiasMu-type opioid receptorP35372T4776825806604
HyperpathiaMu-type opioid receptorP35372T4776825806604
HyperpathiaMitogen-activated protein kinase 8P45983T4009725806604
HyperpathiaProtein kinase C alpha typeP17252T1280825806604
HyperpathiaMu-type opioid receptorP35372T477688383026; 1528399; 1654493; 8490741; 1279757; 7521466
HyperpathiaTranscription factor JunP05412T6908525806604
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.009--Not Available
Chest pain08.01.08.002; 02.02.02.011; 22.02.08.003--Not Available
Cheyne-Stokes respiration22.02.01.024--Not Available
Chills15.05.03.016; 08.01.09.001--
Choking22.02.05.001--Not Available
Cholelithiasis09.03.01.002--Not Available
Cholestasis09.01.01.001--Not Available
Chronic obstructive pulmonary disease22.03.01.007--Not Available
Circadian rhythm sleep disorder19.02.06.002; 17.15.06.0020.000937%Not Available
Circulatory collapse24.06.02.0010.002109%Not Available
Clonus17.02.05.0020.000937%Not Available
Coagulopathy01.01.02.0010.001284%Not Available
Cold sweat23.02.03.002; 08.01.03.0240.001640%Not Available
Colitis ulcerative10.02.01.004; 07.08.01.005--Not Available
Coma17.02.09.0010.009841%Not Available
Compartment syndrome24.04.05.006; 15.05.05.0050.002343%Not Available
Completed suicide08.04.01.010; 19.12.01.0010.012041%Not Available
Confusional state19.13.01.001; 17.02.03.0050.029756%
Conjunctivitis06.04.01.002; 11.01.06.012--
Constipation07.02.02.0010.021556%
Coordination abnormal17.02.02.004--Not Available
Cough22.02.03.001--
Cough decreased22.02.03.006--Not Available
Crying12.02.11.001; 08.01.03.005; 19.04.02.002; 17.02.05.013--Not Available
Cyanosis24.03.01.007; 22.02.02.007; 02.01.02.0020.004920%
Deafness04.02.01.0010.001874%Not Available
Death08.04.01.0010.033739%
Decubitus ulcer23.03.11.006--Not Available
Dehydration14.05.05.001--
Delirium19.13.02.0010.016167%
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 21 Pages